Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Annual NDA Report Sheds Light On SFDA Thinking, Highlights Pediatric Indications, Orphan Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

China’s State FDA handed out 242 new, and 336 abbreviated new, drug approvals in 2012. Pfizer’s Sutent was one of two products that gained a nod without the need for clinical trials.

You may also be interested in...



Insider Analysis From Easton Associates: Are Patient Assistance Programs The Silver Bullet To Meet Affordability Challenges In China?

By Celia Deng, Zhiyi Tong and Paul Zhang

Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China

Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement schemes. As uncertainties mount, companies need to focus on improving process and scale-up technology, suggested industry observers at a JPM panel discussion on innovation and market access challenges.

Diagnostics Sector On High Alert As Wuhan Coronavirus Spreads

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, diagnostics companies are rushing to have test kits ready.

Topics

Related Companies

UsernamePublicRestriction

Register

PS075383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel